Lyphochek Whole Blood Immunosuppressant Control

Date: 
2008-01-18
 

Product Press Release

HERCULES, CA – January 18, 2008 – Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics products, announces the release of Lyphochek® Whole Blood Immunosuppressant Control. This lyophilized, third party, human whole blood based control offers five individual levels and includes Cyclosporine, Tacrolimus, and Sirolimus. Lyphochek Whole Blood Immunosuppressant Control was designed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. It can be used with immunoassay or chromatographic techniques. Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection.

Routine use of Lyphochek Whole Blood Immunosuppressant Control provides a laboratory the means to monitor the precision of test procedures and ensure quality on an ongoing basis.Lyphochek Whole Blood Immunosuppressant Control is supplied as a whole blood based material that can be processed in the same manner as patient samples.

The Unity™ Interlaboratory Program and the Unity Real Time™, an expert data management software solution designed to improve the effectiveness of quality control processes, are available for use with Lyphochek Whole Blood Immunosuppressant Control.

With over 30 years experience as a leading provider of quality control products, Bio-Rad Laboratories offers superior technical support and troubleshooting assistance.


About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www. bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

For more information contact:
Tina Cuccia, Corporate Communications Manager
Bio-Rad Laboratories, Inc.
510-724-7000
Email: tina_cuccia@bio-rad.com